Survival similar for Black, White prostate cancer patients in clinical trial setting

by

For metastatic castration-sensitive prostate cancer (mCSPC), overall survival and progression-free survival are similar for Black and White patients receiving first- or second-generation androgen receptor pathway inhibitors within a clinical trial, according to a study published online Aug. 1 in JAMA Network Open.

Leave A Comment

Your email address will not be published. Required fields are marked *